(Q43691248)

English

Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial

scientific article published on 20 December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

0 references

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

6

object named as

René S Kahn

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Elizabeth Pappadopulos

4

object named as

Elizabeth Pappadopulos

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

author name string

W Wolfgang Fleischhacker

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Cynthia O Siu

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Onur N Karayal

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

EUFEST study group

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

20 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

The International Journal of Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

987-995

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Arterial structure and function in young adults with the metabolic syndrome: the Cardiovascular Risk in Young Finns Study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Prevalence of coronary heart disease risk factors and screening for high cholesterol levels among young adults, United States, 1999-2006

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Metabolic syndrome--what is the clinical usefulness?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001-2006.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Metabolic syndrome associated with schizophrenia and atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Abdominal obesity and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

A Systematic Review of Mortality in Schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

The metabolic syndrome: requiescat in pace

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Severe mental illness and risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Course of illness in a sample of 265 patients with first-episode psychosis--five-year follow-up of the Danish OPUS trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

21 January 2018

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifying metabolic syndrome without blood tests in young adults--The Terneuzen Birth Cohort

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Dropouts and missing data in psychiatric clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic side effects of antipsychotic medication

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

The design and analysis of longitudinal studies of development and psychopathology in context: statistical models and methodological recommendations.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712001241

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S1461145712001241

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43691248&oldid=2102610836"